Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Gastric Cancer Management and Outcomes, Esophageal Cancer Research and Treatment, Colorectal Cancer Treatments and Studies, and Gastrointestinal Tumor Research and Treatment.
Immune Checkpoint Inhibitor Therapy for Advanced, Unresectable Esophageal Squamous Cell Carcinoma: A Series of Patient-level Meta-analyses From Phase III Trials
Impact and effective management of nausea/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies
Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons.
Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.
A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer.
How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force
How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force.
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma
The human crisis in cancer: a Lancet Oncology Commission.
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma.
Targeting HER2 in Gastroesophageal Cancer: A New Appetite for an Old Plight.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer
PD-1/PD-L1 inhibitors in advanced, unresectable esophageal squamous-cell carcinoma: A meta-analysis of their effects across patient subgroups
PD-1/PD-L1 inhibitors in advanced, unresectable esophageal squamous-cell carcinoma: A meta-analysis of their effects across patient subgroups.
Dedicated centres and multinational platforms to improve patient care and address early-onset cancers.
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis.
Expanding therapeutic options targeting claudin-18.2.
Impact of Long-Term Chemotherapy on Outcomes in Pancreatic Ductal Adenocarcinoma: A Real-World UK Multi-Centre Study.
Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study.
Abstract B064: Utility of ctDNA assessment after six weeks of immunotherapy to predict radiological response in advanced esophageal cancer
Promising investigational agents for gastro-oesophageal junction adenocarcinoma.
Corrigendum to "Outcomes of patients with refractory upper GI cancers enrolled in phase I trials: a 10-year analysis from the Sarah Cannon Research Institute UK Drug Development Unit".
Research priorities for cancers of the oesophagus and stomach: recommendations from a UK and Ireland patient and healthcare professional partnership exercise.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer
European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)
European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4).
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023